OpenEvidence, an AI-powered healthcare platform, recently secured $210 million in new funding. Google Ventures and Kleiner Perkins Caufield & Byers co-led this Series B round.
This investment values the company at $3.5 billion.
Founded in 2021, OpenEvidence transforms how clinicians access and apply medical knowledge. The company offers an AI-powered search and decision-support platform. This system assists doctors with high-stakes clinical decisions at the point of care. Furthermore, the platform builds upon peer-reviewed medical literature from trusted sources, including the Journal of the American Medical Association and the New England Journal of Medicine. This allows physicians to surface evidence-based insights rapidly, eliminating traditional database inefficiencies.
OpenEvidence’s primary offering is a clinician-facing AI search interface. Users input patient-specific questions or clinical scenarios. The system then provides tailored, referenced answers based on the latest medical research. This Health Insurance Portability and Accountability Act-compliant system meets the unique demands of frontline healthcare, where decisions often require immediate action.
OpenEvidence's platform currently serves over 10,000 hospitals and medical centers across the U.S. Over 40% of American physicians utilize its capabilities. This widespread adoption highlights the demand for advanced medical technology.
The company distinguishes itself through strategic content partnerships with major medical publishers. Formal agreements with organizations like the American Medical Association ensure access to high-quality, full-text content. This enhances the platform's output, providing rigorously verified medical evidence. While other AI healthcare startups exist, OpenEvidence focuses on deep integration with authoritative medical sources.
Alongside the funding announcement, OpenEvidence also released DeepConsult. This AI agent is purpose-built for physicians. DeepConsult provides doctors with a personal team of Ph.D.-level, medically specialized AI agents. These agents conduct advanced medical research, freeing up physician time. This innovation further differentiates OpenEvidence from general clinical knowledge bases like UpToDate or broader AI initiatives such as Merative. Sequoia Capital Operations, Coatue Management, Conviction Capital, and Thrive Capital Management also participated.
